ArticleVaccines2021
COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.Systematic reviews · 2024Pooled it
- Epidemiological impacts of nonpharmaceutical interventions are modulated by immunity exposure trade offs.Communications medicine · 2026Article
- A Probabilistic Modeling Analysis of the Longitudinal Immune Response to Infection and Vaccination Across Demographic Groups and Pulmonary Symptoms.Spora : a journal of biomathematics · 2026Article
- Probabilistic Modeling of Antibody Kinetics Post Infection and Vaccination: A Markov Chain Approach.ArXiv · 2025Article
- Evaluating COVID-19 vaccination policy in Québec (Canada) using a data-driven dynamic transmission model.PLoS computational biology · 2025Article
- Impact of vaccination on Omicron's escape variants: Insights from fine-scale modelling of waning immunity in Hong Kong.Infectious Disease Modelling · 2025Article
- Prevalence Estimation Methods for Time-Dependent Antibody Kinetics of Infected and Vaccinated Individuals: A Markov Chain Approach.Bulletin of mathematical biology · 2025Article
- Canadian Covid-19 pandemic public health mitigation measures at the province level.Scientific data · 2023Article
- Pharmaceutical and non-pharmaceutical interventions for controlling the COVID-19 pandemic.Royal Society open science · 2023Article
- Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022.Scientific reports · 2023Article
- Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex.Scientific reports · 2022Article
- The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.Vaccine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
COVID-19 seroprevalence changes over time, with infection, vaccination, and waning immunity. Seroprevalence estimates are needed to determine when increased COVID-19 vaccination coverage is needed, and when booster doses should be considered, to reduce the spread and disease severity of COVID-19 infection. We use an age-structured model including infection, vaccination and waning immunity to estimate the distribution of immunity to COVID-19 in the Canadian population. This is the first mathematical model to do so. We estimate that 60-80% of the Canadian population has some immunity to COVID-19 by late Summer 2021, depending on specific characteristics of the vaccine and the waning rate of immunity. Models results indicate that increased vaccination uptake in age groups 12-29, and booster doses in age group 50+ are needed to reduce the severity COVID-19 Fall 2021 resurgence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.